Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


56P - Continuation treatment with immunotherapy beyond two years in patients with metastasic non-small cell lung cancer: retrospective analysis of optimal duration treatment.


06 Oct 2021




Pellicer Boigues Andres Vicente


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


P.B. Andres Vicente1, J. Garde Noguera2, J. García Sanchez2, N. Piera2, T. Fenollosa Sanz2, P. Llor Rodriguez2, J. Iranzo Barreira2, P. Riquelme Cabrera2, M.L. Fernandez Murga Chavanne2, A. Llombart Cussac2

Author affiliations

  • 1 Hospital Arnau de Vilanova, Valencia/ES
  • 2 Hospital Arnau de Vilanova, 46015 - Valencia/ES

Abstract 56P


Immunotherapy (IO) with antiPD1/PD-L1 antibodies is a standard treatment for advanced non-small cell lung cancer (NSCLC), with higher benefits with PDL1+. However, optimal duration of treatment remains unknown. In some pivotal trials, IO was given until disease progression or toxicity, and others limited treatment to two years. This study aimed to assess if continuation therapy with antiPD1/PDL1 therapies in advanced NSCLC past two years is superior to shorter treatment.


Retrospective study of patients treated with antiPD1/PDL-1 therapies for advanced NSCLC in a single institution. Two groups were performed: patients treated past two years (group1); patients who stopped treatment after two years or before due to toxicity (group2). To evaluate survival, Cox regression analysis and Kaplan Meier curves with log-rank were performed.


27 patients fulfilled inclusion criteria: 7 patients (group1) and 20 patients (group2). Toxicities by which immunotherapy was suspended were pneumonitis (n=6), cutaneous (n=4), gastrointestinal (n=3), hypophysis (n=2), hepatitis and keratitis (n=1). Patients’ characteristics: average age was 69, 96% were smokers or former smoker and 81.5% adenocarcinomas; 12 patients received immunotherapy as first and 13 as second-line. 3 complete response, 13 partial responses and 11 stable disease were achieved. Overall survival (OS) was 21.61 months (Group1) vs 11.78 months (Group 2), p=0.19. Progression-free survival (PFS) was 15.23 months (Group1) vs 11.86 months (Group2), p=0.206. Differences in OS were observed when the analysis was performed comparing treatment duration >1 vs ≤1year (OS: 21.96 vs 10.90 months, p=0.029;); not if compared >18 vs 18months (OS: 22.9 vs 11.97 months, p=0.091). Two patients from group 2 were retreated with immunotherapy at disease progression, colitis and pneumonitis reappeared requiring definitive suspension.


In our series, a favorable trend is observed in OS and PFS in patients who were treated beyond two years; differences were statistically significant for patients treated >1 year. Retrospective nature and small sample of patients condition our results and limit their interpretation.

Legal entity responsible for the study

A.V. Pellicer Boigues.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.